Study design
MAY
This phase 1, open-label, single-ascending-dose study of inclacumab in healthy participants was conducted at a single clinical facility (Linear Clinical Research, Nedlands, Western Australia) between September 2020 and May 2021 (Clinical Trial Registry: ACTRN12620001156976). All participants provided written informed consent before the commencement of any study